Know Cancer

or
forgot password

A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
Malignant Glioma

Thank you

Trial Information

A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas


This is a single-institution Phase I/II study designed to evaluate the safety, the induction
of an immune response, and the preliminary clinical response of vaccinations with Type-1
αDCs (αDC1) loaded with glioma-associated antigen (GAA) epitopes and administration of
poly-ICLC in patients with recurrent malignant gliomas. The hypothesis is that this form of
vaccines in combination with poly-ICLC treatment will prove to be safe, and will induce
potent anti-glioma immune responses.

The primary objective is to establish the safety of the approach.

The secondary objectives are to 1) assess the immunological response against GAAs in
patients with recurrent malignant gliomas immunized with DCs loaded with GAA-derived
peptides using enzyme-linked immuno-spot (ELISPOT), delayed-type hypersensitivity (DTH) and
tetramer assays and 2) assess the preliminary anti-tumor clinical activity of the vaccines
as measured by radiological response (MRI), overall survival, and four- and six-month
progression-free survival (PFS).


Inclusion Criteria:



- Patients must have a histologically confirmed

- recurrent glioblastoma (GBM)

- anaplastic astrocytoma (AA)

- anaplastic oligodendroglioma (AO)

- anaplastic mixed oligoastrocytoma (AMO)

- other anaplastic glioma

- Patients must have received prior external beam radiotherapy and/or chemotherapy
unless patients refused the options.

- Patients may have had treatment for no more than 2 prior relapses. Relapse is defined
as progression following initial therapy (i.e. radiation +/- chemo if that was used
as initial therapy).

- Patients must be HLA-A2 positive.

- All patients must sign an informed consent document indicating that they are aware of
the investigational nature of this study.

- Patients must sign an authorization for the release of their protected health
information.

- Patients must be > 18 years old, and with a life expectancy > 8 weeks. -Patients must
have a Karnofsky performance status of > 60.

- Patients must have recovered from the toxic effects of prior therapy: 4 weeks from
any investigational agent, 4 weeks from prior cytotoxic therapy and/or at least two
weeks from vincristine, 4 weeks from nitrosoureas, 3 weeks from procarbazine
administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen,
thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count). Any questions
related to the definition of non-cytotoxic agents should be directed to the principal
investigator.

- Patients must not have any disease that will obscure toxicity or dangerously alter
drug metabolism.

- Patients must not have any serious concurrent medical illness.

- Documented negative serum beta-HCG for female patients of child-bearing age.

- Patients must be free of systemic infection. Subjects with active infections (whether
or not they require antibiotic therapy) may be eligible after complete resolution of
the infection. Subjects on antibiotic therapy must be off antibiotics for at least 7
days before beginning treatment.

- Patients must have adequate organ function as measured by:

1. Hematopoietic:

- granulocytes at least 2500/mm3

- lymphocytes at least 1000/mm3

- platelets at least 100,000/mm3

- hemoglobin at least 10.0 g/dL

2. Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection
fraction at rest must be at least 50% or within the normal range of the
institution. A cardiology clearance will be required for LV ejection fraction
50%.

3. Hepatic: AST, ALT, GGT, LDH, Alk phos within 2.5 x upper normal limit and total
bilirubin no greater than 2.0 mg/dL.

4. Renal: Serum creatinine up to 1.5 x upper normal limit.

5. Pretreatment baseline evaluations for laboratory parameters must be obtained
within 10 to 18 days of subject registration.

Exclusion Criteria:

- Pregnant or breast-feeding.

- Presence of metastatic disease.

- Active bacterial, viral or fungal infections. Subjects with active infections
(whether or not they require antibiotic therapy) may be eligible after complete
resolution of the infection. Subjects on antibiotic therapy must be off antibiotics
for at least 7 days before beginning treatment.

- Chemotherapy, biologic therapy or radiation therapy less than one month prior to
study entry.

- History or presence of autoimmune disease.

- Use of immunosuppressives within 4 weeks prior to study entry or anticipated use of
immunosuppressive agents. Minimum doses of corticosteroid (dexamethasone up to 4
mg/day) is permitted.

- Subjects with uncontrolled pain. -Subjects who have sensitivity to drugs to provide
local anesthesia.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary goal is to establish the safety of the approach.

Outcome Time Frame:

Continuous

Safety Issue:

Yes

Principal Investigator

Frank Lieberman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Pittsburgh

Authority:

United States: Food and Drug Administration

Study ID:

05-115

NCT ID:

NCT00766753

Start Date:

December 2006

Completion Date:

December 2013

Related Keywords:

  • Malignant Glioma
  • HLA-A2 positive
  • Malignant Gliomas
  • Vaccine
  • Glioma

Name

Location

Hillman Cancer CenterPittsburg, Pennsylvania  15232